menu
    • menu

    Company profile for Allegro Ophthalmics

    NEW Drugs in Dev: 2
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We’re bringing innovation to the eye care space with integrin-regulating therapy, a new class of drugs for the treatment of ocular diseases. Risuteganib (Luminate®), our primary investigational compound, is leading the charge with a novel mechanism of action that regulates multiple pathways of oxidative stress response, including mitochondrial dysfunction, which contribute to diseases such as intermediate non-exudative ag...
    We’re bringing innovation to the eye care space with integrin-regulating therapy, a new class of drugs for the treatment of ocular diseases. Risuteganib (Luminate®), our primary investigational compound, is leading the charge with a novel mechanism of action that regulates multiple pathways of oxidative stress response, including mitochondrial dysfunction, which contribute to diseases such as intermediate non-exudative age-related macular degeneration (intermediate dry AMD) and diabetic macular edema (DME).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Allegro OphthalmicsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    31473 Rancho Viejo Road, Suite 204 San Juan Capistrano, CA 92675
    Telephone
    Telephone
    +1 949.940.8130
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.allegroeye.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Allegro Receives FDA Agreement Under SPA for Phase 2b/3 Trial of Risuteganib
    Allegro Receives FDA Agreement Under SPA for Phase 2b/3 Trial of Risuteganib

    12 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/allegro-ophthalmics-receives-fda-agreement-under-special-protocol-assessment-spa-for-phase-2b3-clinical-trial-of-risuteganib-for-the-treatment-of-intermediate-dry-amd-301795701.html

    PR NEWSWIRE
    12 Apr 2023
    Share Share
    Allegro Announces Presentation of Data Surrounding Dry AMD Pipeline Candidates
    Allegro Announces Presentation of Data Surrounding Dry AMD Pipeline Candidates

    10 Feb 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/allegro-ophthalmics-announces-presentation-of-key-data-surrounding-dry-amd-pipeline-candidates-treatment-considerations-301743462.html

    PR NEWSWIRE
    10 Feb 2023
    Share Share
    U.S. Phase 2 Study Published in OSLI Retina on Safety of Risuteganib
    U.S. Phase 2 Study Published in OSLI Retina on Safety of Risuteganib

    04 Aug 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210803005410/en

    BUSINESSWIRE
    04 Aug 2021
    Share Share
    William J. Link, PhD, Named Chairman of Allegro Ophthalmics’ Board of Directors
    William J. Link, PhD, Named Chairman of Allegro Ophthalmics’ Board of Directors

    22 Jun 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210622005431/en

    BUSINESSWIRE
    22 Jun 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search